{"id":"W3026032531","doi":"10.1016/s2213-2600(20)30225-3","title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","year":2020,"lang":"en","type":"review","venue":"The Lancet Respiratory Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":1116,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Roche Products; Canadian Pulmonary Fibrosis Foundation; GlaxoSmithKline","keywords":"Medicine; Pulmonary fibrosis; Pneumonia; Internal medicine; Idiopathic pulmonary fibrosis; Pandemic; Intensive care medicine; Fibrosis; ARDS; Diffuse alveolar damage; Disease; Coronavirus; Coronavirus disease 2019 (COVID-19); Immunology; Lung; Acute respiratory distress; Infectious disease (medical specialty)","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}